Rezaei Fatemeh, Mazidimoradi Afrooz, Pasokh Zahra, Dehghani Seyed Parsa, Allahqoli Leila, Salehiniya Hamid
Research Center for Social Determinants of Health Jahrom University of Medical Sciences Jahrom Iran.
Shiraz University of Medical Sciences Shiraz Iran.
Aging Med (Milton). 2024 Jan 10;6(4):386-426. doi: 10.1002/agm2.12277. eCollection 2023 Dec.
This study aims to describe temporal trends of thyroid cancer (ThC) from 2010 to 2019, in Asian countries by geographical region and sociodemographic index, compared with global data.
Annual case data and age-standardized rates (ASRs) of epidemiological indicators of ThC cancer data were collected from the 2019 Global Burden of Disease (GBD) study from 2010 to 2019 in 49 countries and territories in Asia. The relative difference (%) between years was used to show comparative variations of ASRs for the indicators studied. The female/male ratio was calculated by dividing female ASRs by male ASRs. Also, these rates were compared between the age group ≥70 years old and younger age groups.
In 2019, more than 50% of ThC cases and deaths occurred in Asian countries. A total of 53% of ThC patients lived in Asia and more than 60% of the global burden of ThC was imposed on Asian countries. From 2010 to 2019, incidences, deaths, prevalence cases, and DALYs number of ThC cancer increased over 1.28-, 1.26-, 1.3-, and 1.2-fold, in Asia, respectively. During this period, the age-standardized incidence rate (ASIR) and the age-standardized prevalence rate (ASPR) of ThC cancer increased by 5% and 8%, respectively, while the age-standardized death rate (ASDR) and the age-standardized DALYs rate (DALYs ASR) of ThC cancer decreased by 6% and 4%, respectively. These trends are different from what happens in other continents. In 2019, age-specific incidence, death, prevalence, and DALY cases of ThC cancer were peaking at 50-54, 75-79, 50-54, and 55-59 years, respectively. In 2019, the highest ASIR and ASPR of ThC cancer was observed in high-income Asia Pacific countries and the highest ASDR and DALYs ASR in Southeast Asia countries. Only high-income Asia Pacific countries experienced a decreasing trend in ASIR and ASPR from 2010 to 2019. ASDR and DALYs ASR have the highest decreasing trend in high-income Asia Pacific. In 2019, among high SDI Asian countries, the Republic of Korea had the highest ASIR and ASPR, and Brunei Darussalam had the highest ASDR and DALYs ASR. The highest ASIR, ASDR, ASPR, and DALY ASR of ThC cancer was found in Lebanon and Malaysia (high-middle SDIs), Vietnam (middle SDIs), and Cambodia and Palestine (low-middle SDIs). Among low SDI Asian countries, Pakistan had the highest ASIR, ASDR, ASPR, and DALY ASR of ThC cancer. All indicators for most countries were higher in women than men.
More than half of the burden of thyroid cancer is imposed on the residents of the Asian continent. Although the incidence and prevalence of this cancer in Asian countries is lower than that of the world, America, and Europe, the highest rate of death from thyroid cancer occurs in Asia and they witness the highest burden of the disease. Therefore, it seems that implementing early detection strategies and increasing access to treatment facilities in Asia is one of the necessities of thyroid cancer control in its residents.
本研究旨在描述2010年至2019年亚洲国家按地理区域和社会人口学指数划分的甲状腺癌(ThC)的时间趋势,并与全球数据进行比较。
从2019年全球疾病负担(GBD)研究中收集了2010年至2019年亚洲49个国家和地区的ThC癌症数据的年度病例数据和流行病学指标的年龄标准化率(ASRs)。各年份之间的相对差异(%)用于显示所研究指标的ASRs的比较变化。女性/男性比率通过女性ASRs除以男性ASRs来计算。此外,还比较了70岁及以上年龄组与较年轻年龄组之间的这些比率。
2019年,超过50%的ThC病例和死亡发生在亚洲国家。共有53%的ThC患者生活在亚洲,亚洲国家承担了全球ThC负担的60%以上。2010年至2019年,亚洲ThC癌症的发病率、死亡率、患病率病例数和伤残调整生命年(DALYs)数分别增长了1.28倍、1.26倍、1.3倍和1.2倍。在此期间,ThC癌症的年龄标准化发病率(ASIR)和年龄标准化患病率(ASPR)分别上升了5%和8%,而ThC癌症的年龄标准化死亡率(ASDR)和年龄标准化DALYs率(DALYs ASR)分别下降了6%和4%。这些趋势与其他大洲的情况不同。2019年,ThC癌症的年龄特异性发病率、死亡率、患病率和DALY病例数分别在50 - 54岁、75 - 79岁、50 - 54岁和55 - 59岁达到峰值。2019年,ThC癌症的最高ASIR和ASPR在高收入亚太国家观察到,最高ASDR和DALYs ASR在东南亚国家。只有高收入亚太国家在2010年至2019年期间ASIR和ASPR呈下降趋势。高收入亚太地区的ASDR和DALYs ASR下降趋势最为明显。2019年,在高社会人口学指数(SDI)亚洲国家中,韩国的ASIR和ASPR最高,文莱达鲁萨兰国的ASDR和DALYs ASR最高。ThC癌症的最高ASIR、ASDR、ASPR和DALY ASR在黎巴嫩和马来西亚(高中等SDIs)、越南(中等SDIs)以及柬埔寨和巴勒斯坦(低中等SDIs)被发现。在低SDI亚洲国家中,巴基斯坦的ThC癌症的ASIR、ASDR、ASPR和DALY ASR最高。大多数国家的所有指标女性均高于男性。
超过一半的甲状腺癌负担落在亚洲大陆居民身上。尽管亚洲国家这种癌症的发病率和患病率低于世界、美洲和欧洲,但甲状腺癌的最高死亡率发生在亚洲,且亚洲见证了该疾病的最高负担。因此,在亚洲实施早期检测策略并增加获得治疗设施的机会似乎是控制其居民甲状腺癌的必要措施之一。